IL6 and rheumatoid arthritis: A similar pattern of lipid changes was also seen with other RA therapies such as DMARDs, and tumor necrosis factor (TNF) alpha inhibitors (see Table 1) which suggests that these changes are not only a result of an intrinsic mechanism of action (IL-6 blockade) but also from decreased inflammation.